Dianna Quan
Overview
Explore the profile of Dianna Quan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
438
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jacoby E, Quan D, Todd E, Shortt J, Smith H, Rafaels N, et al.
Muscle Nerve
. 2024 Dec;
71(2):252-256.
PMID: 39655870
Introduction/aims: Hereditary transthyretin amyloidosis (ATTRv) is a genetic condition caused by pathogenic variants in the transthyretin (TTR) gene resulting in multisystem amyloid deposition, especially in peripheral nerve and heart. Information...
2.
Howard I, Tan F, Irwin R, Laughlin R, Chiodo A, Grant P, et al.
PM R
. 2024 Oct;
17(3):347-348.
PMID: 39444112
No abstract available.
3.
Luigetti M, Quan D, Berk J, Conceicao I, Misumi Y, Chao C, et al.
Neurol Ther
. 2024 Mar;
13(3):625-639.
PMID: 38512694
Introduction: Hereditary transthyretin (ATTRv, v for variant) amyloidosis is a rare, progressive, fatal disease with multisystem manifestations, caused by pathogenic variants in the transthyretin (TTR) gene. Vutrisiran, an RNA interference...
4.
Antozzi C, Guptill J, Bril V, Gamez J, Meuth S, Nowak R, et al.
Neurology
. 2024 Jan;
102(2):e207937.
PMID: 38165333
Background And Objectives: To evaluate in a phase 2 study the safety and efficacy of IV nipocalimab, a fully human, antineonatal Fc receptor monoclonal antibody, in patients with generalized myasthenia...
5.
Dixon S, Kang X, Quan D
Ther Clin Risk Manag
. 2023 Dec;
19:973-981.
PMID: 38047038
Variant transthyretin amyloidosis (ATTRv) is an autosomal dominant inherited genetic disorder that affects 5000-10,000 people worldwide. It is caused by mutations in the transthyretin (TTR) gene and results in amyloid...
6.
Quan D, Obici L, Berk J, Ando Y, Aldinc E, White M, et al.
Amyloid
. 2022 Sep;
30(1):49-58.
PMID: 36120830
Objective: Assess how baseline polyneuropathy severity impacts response to patisiran regarding neurologic impairment and quality of life (QOL) in patients with hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis). Methods: This analysis grouped...
7.
Nowak R, Coffey C, Goldstein J, Dimachkie M, Benatar M, Kissel J, et al.
Neurology
. 2021 Dec;
98(4):e376-e389.
PMID: 34857535
Objective: To determine whether rituximab is safe and potentially beneficial, warranting further investigation in an efficacy trial for acetylcholine receptor antibody-positive generalized MG (AChR-Ab+ gMG). Methods: The B-Cell Targeted Treatment...
8.
Kang X, Quan D
Neurol Clin
. 2021 Oct;
39(4):1071-1081.
PMID: 34602215
Motor neuron diseases involve degeneration of motor neurons in the brain (upper motor neurons), brain stem, and spinal cord (lower motor neurons). Symptoms vary depending on the degree of upper...
9.
Adams D, Polydefkis M, Gonzalez-Duarte A, Wixner J, Kristen A, Schmidt H, et al.
Lancet Neurol
. 2020 Nov;
20(1):49-59.
PMID: 33212063
Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an...
10.
Shefner J, Andrews J, Genge A, Jackson C, Lechtzin N, Miller T, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2020 Sep;
22(3-4):287-299.
PMID: 32969758
To evaluate safety, dose response, and preliminary efficacy of over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). Patients (≤2 years since diagnosis) with slow upright vital capacity (SVC)...